BioWorld Asia

Dec. 15, 2004

MediGene's Phase III Drug Effective In Genital Warts

MUNICH, Germany - MediGene AG completed its second Phase III trial of Polyphenon E, a treatment for genital warts, getting significant clinical effects compared to placebo, as well as good tolerability. (BioWorld International) Read More

Chroma Raises £5M More To Add To Second Round

New Antibiotic Class Might Thrash Drug-Resistant TB

European Report: New Biotech Products Should Rise In Future

Pepscan Enters Vaccine Deal Aimed At Cytokine With Cytos

ExonHit Hits First Milestone In Partnership With Allergan

Cresset Using FieldScreen As Drug Discovery Platform

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Black wavy lines forming an abstract sound wave.png

Deep brain stimulation from the shallows: tomorrow’s BCI technology?

BioWorld

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...